We are a research-based/commercial-stage, biopharmaceutical company dedicated to the identification, development and commercialization of novel therapies that improve function in people affected by a number of medical conditions in a variety of complexities and situations, no matter what clinical stage they reached as it happens in multiple sclerosis, or MS, spinal cord injury, or SCI, and other disorders of the nervous system, as example. We have marketed evolutionary active principles and molecules as well as developmental stage products and are working to bring important new therapies to people with different disorders. Our goal is to help patients to a better future, while building a leading neurology company with a portfolio of innovative products.
As example, Approximately 400,000 people in the U.S. suffer from MS, and each year approximately 10,000 people in the U.S. are newly diagnosed. Research indicates that 64% to 85% of those people experience walking disability and that 70% of people with MS who have difficulty walking report it to be the most challenging aspect of their MS. Within 15 years of an MS diagnosis, 50% of people with MS often require assistance walking and, in later stages, up to one third are unable to walk. Even in early stages of the disease, walking can be a significant issue; one study found that 28% of people reported walking disabilities within two years of MS diagnosis. In the European Union (EU), approximately 600,000 people suffer from MS, and an additional 55,000 to 75,000 people in Canada are also diagnosed with this disease.
We are developing what we believe is an industry leading pipeline of novel therapies. We are developing novel treatments for selected, refractory patients with epilepsy, schizophrenia and/or headache, facial pain and trigeminal neuralgia as well as others based on stable regimens of anti-epileptic drugs, or AEDs, or single-dose treatment for those who require intermittent use of certain molecules to control bouts of increased activity also known as cluster or acute repetitive episodical onsets, or AREO´s. We are also studying new treatment frontiers to improve a range of functional impairments, in addition to walking disability, caused by MS, as well as its potential use of other peptide and non-peptide derived molecules in other neurological conditions, including cerebral palsy and post-stroke deficits. In addition, we are developing clinical stage compounds for acute treatment of SCI, different novel approaches for treatment of heart failure, and a highly promissory compound and formula based on a specific remyelinating monoclonal antibody, for the treatment of MS.
This business unit is focused on service to clients from
different fields from academia to government labs
as well as companies in the food, nutrition,
health and medical sectors, including pharmaceuticals
and biopharmaceuticals. The aim of this unit is to
develop innovative tools and solutions to let our
clients to enter into the complex areas of research t
hat are demanding solutions in the evolved and ever-growing society.
We have created a leading portfolio of chemicals and biological
compounds that is growing to impulse our sales channels.
This business unit serves customers that are in the business
of manufacturing final products from different sectors
from life sciences to construction and building or electronics.
Our customers require certain raw materials that have an
important impact on the performance of their industries
and businesses as well as over their final products and
competitive capacity. Our aim is to play an integral role in
their business providing the molecules, compounds a
nd products that they demand constantly.
Market for our products and solutions are growing exponentially
as far as is growing the amount of clients and prospective
clients that are using our products or analogues in their
ordinary business and production. We want to be focused also
in that kind of client. Those companies will be profiting from
the use of advanced solutions and research from us,
since they are not in the position for developing
their own technologies and science.